In this article, we will discuss Durvalumab (Indication-1). So, let’s get started.
- Non-Small Cell Lung Cancer
- Durvalumab is indicated for the treatment of adult patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.